| Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond. | |
| | |
MedLine Citation:
|
PMID: 17883987 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Erythropoietin (EPO) is a glycoprotein hormone implicated in the regulation of red blood cell production. Anemia is common in chronic heart failure (CHF) patients and associated with an inappropriately low EPO-production, suggesting a role for its recombinant human form (rhEPO) in treatment. Although safety concerns have been raised regarding treatment with rhEPO in patients with chronic kidney disease, treatment with rhEPO in patients with CHF has so far been safe and well tolerated. The effect of rhEPO on outcome in anemic CHF patients is under investigation in a phase III clinical trial. In addition to its erythropoietic effects, EPO has been detected in the cardiovascular system, fueling intense research into possible non-hematopoietic effects. EPO has been shown to exert protective effects on the heart during acute myocardial ischemia and improve cardiac function in experimental CHF. Acute protection is mediated through reduction of apoptotic cell death. Improvement of cardiac function in CHF is related to myocardial neovascularization. EPO exhibits a vast array of beneficial effects in cardiovascular disease. In addition to the correction of anemia in CHF, rhEPO might benefit patients with cardiovascular disease. |
| | |
Authors:
|
B Daan Westenbrink; Adriaan A Voors; Willem-Peter T Ruifrok; Wiek H van Gilst; Dirk J van Veldhuisen |
Related Documents
:
|
8957547 - Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy... 11835907 - From the hope to the ontarget and the transcend studies: challenges in improving progno... 3041387 - Cardiovascular drugs in children: angiotensin-converting enzyme inhibitors. 12189297 - Diagnosis and assessment in heart failure. 3831017 - Assessment of left ventricular function before and after fontan's operation for the cor... 12555167 - Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyo... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current heart failure reports Volume: 4 ISSN: 1546-9530 ISO Abbreviation: Curr Heart Fail Rep Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-09-21 Completed Date: 2007-12-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101196487 Medline TA: Curr Heart Fail Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 127-33 Citation Subset: IM |
Affiliation:
|
University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9700 RB Groningen, The Netherlands. b.d.westenbrink@thorax.umcg.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cardiovascular Diseases / blood, drug therapy* Erythropoiesis / drug effects* Erythropoietin, Recombinant / therapeutic use* Humans Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Erythropoietin, Recombinant |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of increased aortic stiffness in the pathogenesis of heart failure.
Next Document: Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure.